Potassium Channel KCNH8 Slows Triple-Negative Breast Cancer by Blocking PI3K-AKT Signaling

Triple-negative breast cancer remains one of the hardest breast cancers to control clinically, largely because recurrence and metastatic disease continue to challenge available treatments. A new open-access study published in Biology Direct points to an unexpected player in this disease: KCNH8, a potassium channel gene whose expression is dysregulated across several cancer types but whose role in breast carcinoma had not been clarified. Combining large-scale database analysis with laboratory experiments, the research team reports that KCNH8 is reduced in breast tumors and that restoring its activity suppresses malignant behavior in triple-negative breast cancer cells.

The investigators first mined GEO and TCGA databases to profile KCNH8 expression, prognosis, methylation status, and immune infiltration features. Across breast tumor samples, KCNH8 expression was lower than in normal tissue, and patients whose tumors retained higher levels of the gene showed improved overall survival and more favorable clinicopathologic characteristics. Methylation of the KCNH8 gene was elevated in tumors and negatively correlated with its expression, suggesting that epigenetic silencing may be one mechanism by which this channel is lost during breast carcinogenesis.

To test whether KCNH8 actively influences cancer cell behavior rather than merely marking a less aggressive disease, the team manipulated its expression in triple-negative breast cancer cells and monitored key malignant phenotypes. Elevating KCNH8 curtailed proliferation, migration, invasion, and epithelial-mesenchymal transition, the cellular program that equips cancer cells to spread. Conversely, depleting KCNH8 enhanced these same malignant traits, consistent with the channel acting as a brake on tumor progression.

The mechanistic link emerged from immunoblot assays: KCNH8 reduced phosphorylation of PI3K and AKT, components of a central growth-signaling pathway that drives survival and proliferation in many cancers. Supporting causality, pharmacologic activation of PI3K partly counteracted KCNH8’s growth-suppressive effects, indicating that the channel’s benefit depends substantially on keeping this pathway in check. In vivo, enforced KCNH8 expression restrained tumor growth in subcutaneous xenografts established in nude mice, extending the cell-culture findings to an animal model.

The authors conclude that KCNH8 is reduced in breast carcinoma and could inhibit tumor progression by suppressing PI3K/AKT pathway activity, positioning the gene as a candidate marker for prognostic assessment. Because the work combines retrospective database analysis with in vitro phenotype assays and mouse xenografts, it establishes an association and a plausible mechanism rather than a validated clinical tool; the article is being shared early as a peer-reviewed, accepted but still editable version of record. Translating these findings into prognostic testing or therapeutic strategies will require further validation in independent patient cohorts and clinical settings.

Subject of Research: The role of the potassium channel KCNH8 in suppressing triple-negative breast cancer progression through PI3K/AKT inhibition.

Article Title: Systematic analysis reveals that KCNH8 suppresses triple-negative breast cancer progression through PI3K‑AKT inhibition

Article References: Wang, Y.-T., Chen, Y.-Z., Shi, J.-J., Zhou, X.-R., Ou, Y., Liu, H., Li, H.-X., & Zhang, J. (2026). Systematic analysis reveals that KCNH8 suppresses triple-negative breast cancer progression through PI3K‑AKT inhibition. Biology Direct. https://doi.org/10.1186/s13062-026-01025-6

Image Credits: AI Generated

DOI: 10.1186/s13062-026-01025-6

Keywords: KCNH8, triple-negative breast cancer, potassium channel, PI3K/AKT pathway, methylation, EMT, xenograft model, prognosis, bioinformatics, tumor suppression, Systematic, analysis